Intrapulmonary Penetration of Voriconazole in Patients Receiving an Oral Prophylactic Regimen-Reference-Cited by-同舟云学术

Intrapulmonary Penetration of Voriconazole in Patients Receiving an Oral Prophylactic Regimen

Published:2006-05 Issue:5 Volume:50 Page:1878-1880
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Capitano Blair¹²,Potoski Brian A.¹²,Husain Shahid²,Zhang Shimin¹,Paterson David L.²,Studer Sean M.³,McCurry Kenneth R.⁴,Venkataramanan Raman¹⁵

Affiliation:

1. School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania

2. Division of Infectious Diseases, University of Pittsburgh, Pittsburgh, Pennsylvania

3. Division of Pulmonary and Critical Care Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania

4. Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania

5. Department of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania

Abstract

ABSTRACT Voriconazole penetrated well into the pulmonary epithelial lining fluid (ELF) in lung transplant patients receiving oral prophylaxis. The ELF concentrations exceeded those of the plasma, with an average ELF-to-plasma ratio of 11 (±8). A strong association between plasma and ELF concentrations ( r 2 = 0.95) was noted.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.50.5.1878-1880.2006

Reference18 articles.

1. Capitano, B., H. M. Mattoes, E. Shore, A. O'Brien, S. Braman, C. Sutherland, and D. P. Nicolau. 2004. Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin and azithromycin in older adults. Chest125:965-973.

2. Single-dose intrapulmonary pharmacokinetics of azithromycin, clarithromycin, ciprofloxacin, and cefuroxime in volunteer subjects

3. Herbrecht, R., D. W. Denning, T. F. Patterson, J. E. Bennett, R. E. Greene, J. W. Oestmann, W. V. Kern, K. A. Marr, P. Ribaud, O. Lortholary, R. Sylvester, R. H. Rubin, J. R. Wingard, P. Stark, C. Durand, D. Caillot, E. Thiel, P. H. Chandrasekar, M. R. Hodges, H. T. Schlamm, P. F. Troke, and B. de Pauw. 2002. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med.347:408-415.

4. Honeybourne, D. 1997. Antibiotic penetration in the respiratory tract and implications for the selection of antimicrobial therapy. Curr. Opin. Pulm. Med.3:170-174.

5. Husain, S., D. B. Zaldonis, E. J. Kwak, and K. R. McCurry. 2004. Role of voriconazole prophylaxis for the prevention of invasive aspergillosis (IA) at six months in lung transplant recipients. J. Heart Lung Transpl.23(Suppl. 1):S110.

Cited by 63 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Renal Replacement Therapy as a New Indicator of Voriconazole Clearance in a Population Pharmacokinetic Analysis of Critically Ill Patients;Pharmaceuticals;2024-05-22

2. Invasive fungal infections and oomycoses in cats 2. Antifungal therapy;Journal of Feline Medicine and Surgery;2024-01

3. Bronchopulmonary penetration of isavuconazole in lung transplant recipients;Antimicrobial Agents and Chemotherapy;2023-10-18

4. Bronchopulmonary Penetration of Isavuconazole in Pulmonary Transplant Recipients (PBISA01): Protocol for a Phase IV Clinical Trial With a Single Treatment Arm;JMIR Research Protocols;2022-09-14

5. Therapeutic Drug Monitoring of Sputum Voriconazole in Pulmonary Aspergillosis;Pharmaceutics;2022-07-30